BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Balaxi Pharmaceuticals has filed a routine quarterly compliance statement under SEBI Regulation 32 confirming there is no deviation or variation in the use of funds raised through its preferential issue of convertible warrants and equity shares (originally allotted on October 11, 2022, with subsequent warrant conversions through April 2024). The company raised a total of approximately Rs. 47.57 crore, of which around Rs. 28.63 crore (about 60%) has been utilised so far. The funds were earmarked for setting up the company's first pharmaceutical formulation plant at Jadcherla, Hyderabad, along with working capital and general corporate purposes. No monitoring agency was appointed, and both the audit committee and auditors had no adverse comments on fund utilisation.
This is a clean, routine compliance filing with no negative findings, indicating that preferential issue proceeds are being deployed as originally communicated. It is broadly reassuring for shareholders but is unlikely to move the stock price materially on its own.